New Lifestyle and Drug Cost Programs for 2027
Medicare introduces several programs in 2027 to address chronic disease management and medication affordability. These initiatives offer tangible support for individuals managing complex health needs.
The Medicare GLP-1 Bridge
For 2027, Medicare launched the GLP-1 Bridge program to widen access to essential medications. It assists qualifying Part D beneficiaries prescribed Glucagon-Like Peptide-1 (GLP-1) drugs for weight loss and health improvement.
If your Part D plan excludes these medications, this bridge program provides access for a flat $50 monthly copayment. This change dramatically lowers financial hurdles for metabolic treatments.
The ACCESS Model for Chronic Care
Original Medicare is introducing the ACCESS model in 2027 for home-based chronic care. This model supports enrollees living with conditions like diabetes, hypertension, and depression.
Participants receive wearable devices, personalized coaching, and regular virtual visits at low or no cost. These services help monitor vital signs at home while reducing unplanned hospital visits.
Medicare Prescription Payment Plan
The Medicare Prescription Payment Plan continues into 2027 to eliminate pharmacy counter sticker shock. It allows spreading out-of-pocket Part D costs into capped monthly installments across the year.
While this option does not reduce total prescription costs, it prevents burdensome upfront payments in January. You can enroll in this payment structure directly through your Part D plan administrator.
TrumpRx Discount Comparisons
The 2027 Medicare handbook introduces TrumpRx.gov, an online tool designed to compare prescription prices. Beneficiaries can compare Part D copayments against cash-discount pharmacy coupons.
However, CMS cautions that purchases made using cash coupons do not count toward your Part D deductible or $2,400 out-of-pocket cap. Review whether coupon savings outweigh losing progress toward your cap.
